The New England Journal of Medicine yesterday published two studies on the effectiveness of the interleukin-6 receptor antagonists tocilizumab and sarilumab in severely ill adult COVID-19 patients, one finding a benefit to a combination of the two drugs and the other showing no benefit with tocilizumab alone.Early treatment with combo may be keyThe first study, led by researchers at Imperial College London as part of an ongoing international platform trial, involved randomly assigning 803 patients in 113 intensive care units (ICUs) in six countries to receive tocilizumab, sarilumab, or usual care from April (tocilizumab) and June (sarilumab) through November 2020.Median number of organ support–free days was 10 in the group receiving